Evidence map›Paper›PMID 37841591›Full record

ArticleiScience2023

Postnatal hyperglycemia alters amino acid profile in retinas (model of Phase I ROP).

Jarrod C Harman, Aldina Pivodic, Anders K Nilsson, Myriam Boeck, Hitomi Yagi, Katherine Neilsen, Minji Ko, Jay Yang, Michael Kinter, Ann Hellström and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 4 countries.

Jarrod C HarmanDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Aldina PivodicThe Sahlgrenska Centre for Pediatric Ophthalmology Research, Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Anders K NilssonThe Sahlgrenska Centre for Pediatric Ophthalmology Research, Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Myriam BoeckDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Hitomi YagiDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Katherine NeilsenDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Minji KoDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Jay YangDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Michael KinterOklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA.
Ann HellströmThe Sahlgrenska Centre for Pediatric Ophthalmology Research, Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Zhongjie FuDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Boston Children's Hospital · USUniversity of Gothenburg · SEOklahoma Medical Research Foundation · US

Funding

Targeted DNA Methylation and Mitochondrial Heteroplasmy CoreP30AG050911 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Matthew John Hart · 2015 to 2026
$13.9M
Dietary control of angiogenesis in retinopathy modelsR01EY017017 · NEI · BOSTON CHILDREN'S HOSPITAL · PI Zhongjie Fu, Lois Smith · 2006 to 2026
$11.8M
Serine control of retinal neovascularization in retinopathyR01EY032492 · NEI · BOSTON CHILDREN'S HOSPITAL · PI FU, ZHONGJIE · 2021 to 2025
$2.2M
NEI NIH HHS R01 EY017017NEI NIH HHS R01 EY032492NIA NIH HHS P30 AG050911
6 · The paper itself

Abstract

Nutritional deprivation occurring in most preterm infants postnatally can induce hyperglycemia, a significant and independent risk factor for suppressing physiological retinal vascularization (Phase I retinopathy of prematurity (ROP)), leading to compensatory but pathological neovascularization. Amino acid supplementation reduces retinal neovascularization in mice. Little is known about amino acid contribution to Phase I ROP. In mice modeling hyperglycemia-associated Phase I ROP, we found significant changes in retinal amino acids (including most decreased L-leucine, L-isoleucine, and L-valine). Parenteral L-isoleucine suppressed physiological retinal vascularization. In premature infants, severe ROP was associated with a higher mean intake of parenteral versus enteral amino acids in the first two weeks of life after adjustment for treatment group, gestational age at birth, birth weight, and sex. The number of days with parenteral amino acids support independently predicted severe ROP. Further understanding and modulating amino acids may help improve nutritional intervention and prevent Phase I ROP.

Indexed as

Biological sciencesDisease

Identifiers

PMID37841591
PMCPMC10568433
OpenAlexW4386969776

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.